CBL-514 is a proprietary first-in-class small-molecule lipolytic agent and high-value pharmaceutical intermediate widely applied in localized fat reduction drug development. As a lyophilized research powder, it features strict purification standards with typical purity ≥99%; standardized bulk batches maintain uniform physical properties for laboratory and preclinical research use.

As the world’s first investigational injectable candidate engineered for large-area targeted subcutaneous fat removal, it delivers exclusive localized fat-regulating effects via dual mechanisms: triggering dose-dependent adipocyte apoptosis and accelerating regional lipolysis. It precisely eliminates fat deposits at injection sites without necrosis or injury to adjacent skin and soft tissues, outperforming traditional non-surgical contouring agents and matching the fat-reduction magnitude of liposuction surgery. Manufactured under standardized pharmaceutical purification workflows, it retains stable molecular activity and consistent pharmacodynamic performance across all production lots.

Readily reconstitutable in sterile water and neutral buffer solutions, CBL-514 exhibits outstanding long-term stability in lyophilized powder form with recommended storage at -20°C under dry, light-shielded conditions. This core research intermediate lays a critical foundation for developing injectable therapies for localized adiposity, cellulite, Dercum’s disease and combined metabolic weight management, creating synergistic value alongside mainstream GLP-1 peptide drugs within the booming global body contouring and obesity treatment pharmaceutical market.